Ideaya Biosciences Inc
Ideaya Biosciences Inc (IDYA) Expected Move
IDYA expected move through Nov 20, 2026 is 12.6%, with 13 days to expiration. The implied range is $27.37 to $35.11, based on the previous trading day's options prices.
Read more
Tracking the IDYA expected move helps you see how far Ideaya Biosciences Inc's options market is pricing the stock to travel over a given period — whether that's the next day, week, or earnings cycle. Ideaya Biosciences Inc's expected move is derived directly from option premiums and gives you an objective range to plan trades, set strikes, and manage risk. Use our scanner to monitor the IDYA expected move for this week's options, in real time.
The expected move is typically calculated from at-the-money straddle prices (or a blend of straddles and strangles) and represents roughly a one-standard-deviation range over the chosen timeframe. For IDYA, comparing the implied expected move to actual realized moves over similar windows tells you whether the options market has historically overestimated or underestimated volatility. The IDYA expected move for this week's options pricing is especially useful for short-dated traders, earnings players, and anyone selling premium who needs to know where the market thinks Ideaya Biosciences Inc is unlikely to go.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability.
Iron condors, weekly premium sales, directional swing trades — they all live or die by where the market thinks the stock won't go. Our scanner tracks the IDYA expected move across every expiration, benchmarks it against realized moves, and shows you when implied ranges are out of line with history. The Ideaya Biosciences Inc expected move for this week's options is the fastest read on short-term risk, which gives you a quick way to interpret what the options market thinks about IDYA.
IDYA Price
Drag chart to pan. Drag axes to zoom.
| Expiration | DTE | Expected move (USD) | Expected move (%) | Upper price | Lower price |
|---|---|---|---|---|---|
| Nov 20, 2026 | 13 | $3.88 | 12.6% | $35.11 | $27.37 |
| Dec 18, 2026 | 41 | $5.56 | 18.1% | $36.80 | $25.68 |
| Jan 15, 2027 | 69 | $6.04 | 19.7% | $37.28 | $25.20 |
| Apr 16, 2027 | 160 | $8.73 | 28.5% | $39.96 | $22.52 |
As of Nov 5, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →